Share

Information on Sartorius Stedim Biotech share (DIM) at a glance

Overview

ISIN

FR0013154002

Stock exchange

Euronext Paris

Market segment

Local Securities - Compartment A (Large Caps)

Indixes

SBF 120 | CAC Next 20 | CAC Large 60 | CAC All-Tradable | CAC All Shares | CAC Healthcare | MSCI France | STOXX Europe 600

Capital stock

18,436,038 euros

Number of shares

92,180,190

- thereof Sartorius AG

73.6%

- thereof free float

26.4%

Voting rights

~161.0 million

- thereof Sartorius AG

~85.0%

- thereof free float

~15.0%

Sartorius Stedim Biotech is currently covered by 13 sell-side analysts. The following list shows their latest recommandations for Sartorius Stedim Biotech shares.


InstitutionAnalystDateTarget Price  Recommendation

Société Générale

Delphine Le Louët

12.09.2022

543.00

Buy

Morningstar

Aaron Degagne

07.09.2022

290.00

--

Morgan Stanley

James Quigley

22.07.2022

465.00

Hold

Berenberg

Odysseas Manesiotis

22.07.2022

464.00

Buy

J.P. Morgan

Richard Vosser

22.07.2022

470.00

Buy

Exane BNP Paribas

Hugo Solvet

22.07.2022

440.00

Buy

Kepler Cheuvreux

Oliver Reinberg

21.07.2022

420.00

Buy

HSBC

Sezgi Özener

22.06.2022

410.00

Buy

UBS

Michael Leuchten

16.05.2022

370.00

Buy

AlphaValue

Virendra Chauhan

25.04.2022

428.00

Buy

Gilbert Dupont

Guillaume Cuvillier

21.04.2022

412.00

Buy

Bank of America Merril Lynch

Patrick Wood

25.03.2022

497.00

Buy

Oddo BHF

Daniel Wendorff

27.01.2022

530.00

Buy

Disclaimer

The analysts’ estimates listed above as examples are not based on research or analyses conducted by Sartorius AG, but rather exclusively on analyses, research, reports, recommendations or ratings of third parties. References to such recommendations and ratings are provided as convenience for readers and for non-binding informational purposes only. These references do not imply that Sartorius AG adopts, endorses or confirms in any way the recommendations, options, opinions, conclusions or estimates of analysts. In particular, analysts’ estimates do not constitute any investment advice given by Sartorius AG. None of the information provided is intended as an offer or encouragement to buy Sartorius shares or other financial instruments, nor is it an offer to purchase or sell.

Sartorius AG shall not assume any liability, in particular for the selection, topicality, quality, completeness or accuracy of the analysts’ estimates shown and, if any, of analysts’ recommendations. Any liability on the part of Sartorius AG for damages or losses incurred by third parties based on the information published on this website shall be excluded.

Sartorius Stedim Biotech strives to enable its shareholders to participate adequately in the company’s success and has continuously increased its dividend in recent years. In line with this objective, we basically follow the policy of paying out a relatively stable share of relevant net profit to our shareholders.

2014

2015

2016

2017

2018

2019

Total dividends paid in millions of €                                                   20.0   30.7    38.7   42.4   

52.5

62.7

Payout ratio 1 in %

22.9

22.1

21.9

23.5

24.0

23.8

Dividend yield 2 in %

0.8

0.6

0.7

0.8

0.7

0.5

1 Based on the underlying net result  2 Dividends in relation to the corresponding closing prices of the year

“Sartorius Stedim Biotech S.A.’s issued capital amounted to €18.4 million as of February 28, 2022, and was divided into 92,180,190 shares, each with a calculated par value of €0.20. As some of the shares convey double voting rights, there were a total of 160,522,434 voting rights as of the reporting date.

As of February 28, 2022, Sartorius AG holds 73.6% of the share capital and 84.6% of the outstanding voting rights. The remaining 26.4% of the shares are in free float; corresponding to 15.4% of the outstanding voting rights.”

Financial Calendar

Learn More

Stock Chart

More Information

Investor Relations Sartorius Stedim Biotech SA

Learn More

News & Publications

Learn More

Sartorius AG Shares

Learn More